Search

Your search keyword '"Chang, Elaine"' showing total 372 results

Search Constraints

Start Over You searched for: Author "Chang, Elaine" Remove constraint Author: "Chang, Elaine"
372 results on '"Chang, Elaine"'

Search Results

1. Refusal-Trained LLMs Are Easily Jailbroken As Browser Agents

6. The contribution of NaV1.6 to the efficacy of voltage‐gated sodium channel inhibitors in wild type and NaV1.6 gain‐of‐function (GOF) mouse seizure control.

7. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop

8. Supplementary Table S2 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

9. Supplementary Figure S1 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

10. Data from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

11. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

13. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials

14. A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma

15. US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.

17. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

19. HepToX: Heterogeneous Peer to Peer XML Databases

21. NaV1.6 inhibition drives the efficacy of voltage-gated sodium channel inhibitors to prevent electrically induced seizures in both wild type andScn8aN1768D/+gain-of-function mice

22. FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.

25. Supplementary Table S1 from Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

27. Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist

34. Survey of the Prevalence of Burnout, Stress, Depression, and the Use of Supports by Medical Students at One School

38. NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats

39. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma

40. Author response: NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats

42. STRUCTURAL BIOLOGY: Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist

43. RE: Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?

44. Identification of aryl sulfonamides as novel and potent inhibitors of NaV1.5

45. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop

50. A gustatory receptor paralogue controls rapid warmth avoidance in Drosophila

Catalog

Books, media, physical & digital resources